← BeOne Medicines Ltd. (ONC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BeOne Medicines Ltd. (ONC)
Pharmaceutical Preparations · market cap $41.1B · as of 2026-10-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
BeOne Medicines (formerly BeiGene) is a multinational oncology company headquartered in Cambridge, MA, with about 12,000 employees, operations in more than 45 countries, and a large presence in China. Revenue grew from $1.18B in 2021 to $5.34B in 2025, and the company reached its first positive net income in our data ($287M in 2025), with $5.1B in cash and roughly $4.0B in net cash. The near-term calendar is led by Q3 earnings (est. 2026-11-05) and a zanubrutinib Phase 2 readout (est. 2026-11-15), and the highest-weighted events are a BGB-16673 Phase 3 (est. 2027-03-15) and a Tacrolimus-labeled Phase 3 in primary membranous nephropathy (est. 2027-10-15).
The catalyst path
- 2026-11-15 (est.)Phase 2 · Sonrotoclaximp 7/10
- 2026-12-01 (est.)Phase 2 · Zanubrutinibimp 7/10
- 2026-12-31 (est.)Phase 3 · Zanubrutinibimp 9/10
- 2026-12-31 (est.)Phase 2 · Fludarabineimp 7/10
- 2027-02-15 (est.)Phase 2 · Zanubrutinibimp 7/10
- 2027-03-15 (est.)Phase 2 · Tacabrutidegimp 7/10
- 2027-03-15 (est.)Phase 2 · BGB-16673imp 7/10
- 2027-03-31 (est.)Phase 2 · BGB-B2033imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Zanubrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| PD-1/PD-L1 inhibitors | Phase 2 | Borderline Resectable Carcinoma |
| Tacabrutideg | Phase 3 | Chronic Lymphocytic Leukemia |
| BGB-16673 | Phase 3 | B-cell Malignancy |
| Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma |
| Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| Sonrotoclax | Phase 3 | Mantle Cell Lymphoma |
| ZW25 (Zanidatamab) | Phase 2 | HER2-amplified Biliary Tract Cancers |
| Leucovorin | Phase 3 | Gastroesophageal Adenocarcinoma |
| Tislelizumab | Phase 3 | Advanced Malignancies |
| BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer |
| CAR-T Cell Therapy | Phase 2 | Mantle Cell Lymphoma |
| Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia |
| Fludarabine | Phase 2 | Recurrent Transformed Chronic Lymphocytic Leukemia |
| BGB-11417 | Phase 2 | Acute Myeloid Leukemia |
| bendamustine | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
| Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma |
| Tacrolimus | Phase 3 | Primary Membranous Nephropathy |
| Oxaliplatin | Phase 3 | Advanced Unresectable Gastric Adenocarcinoma |
| BGB-A445 | Phase 3 | Advanced Malignancies |
Price & technical context
3-month
+11.2%
6-month
+22.2%
12-month
+25.2%
52-wk range
$260.27–$387.25
vs 50-day MA
+6.7%
vs 200-day MA
+19.0%
Realized vol
35.6%
Max drawdown
-31.0%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ONC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.